NHAS
IOVA icon

Novo Holdings A/S’s Iovance Biotherapeutics IOVA Stock Holding History

Novo Holdings A/S’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-836,518
Closed -$13.9M – 55
2022
Q1 		$13.9M Hold
836,518
– – 0.73% 26
2021
Q4 		$16M Hold
836,518
– – 0.76% 26
2021
Q3 		$20.6M Buy
836,518
+161,358
+24% +$3.8M 1.07% 20
2021
Q2 		$17.6M Buy
675,160
+213,349
+46% +$5.55M 0.78% 27
2021
Q1 		$14.6M Buy
461,811
+77,694
+20% +$3.22M 0.6% 30
2020
Q4 		$17.8M Sell
384,117
-821
-0.2% -$32.6K 0.76% 24
2020
Q3 		$12.7M Buy
+384,938
New +$11.8M 0.63% 24

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Novo Holdings A/S's IOVA Position: Q2 2022 in Review

Novo Holdings A/S sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 836,518 shares — an estimated $13.9M sold.

Novo Holdings A/S first reported a position in IOVA in Q3 2020 and held it in 7 quarters. The position peaked at $20.6M in Q3 2021. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Novo Holdings A/S reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Novo Holdings A/S sold 836,518 Iovance Biotherapeutics shares in Q2 2022, an estimated $13.9M.
  • Novo Holdings A/S first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 7 quarters.
  • Novo Holdings A/S's Iovance Biotherapeutics position peaked at $20.6M in Q3 2021.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Novo Holdings A/S's 13F filing for Q2 2022, filed 15 Aug 2022.